Promoter shareholding increased slightly by 0.57% YoY, indicating stable insider confidence amidst a stagnant sector; however, no QoQ change suggests a lack of fresh investment.

Institution and Public shareholding remained unchanged, reflecting a broader trend of selling across the Pharma sector, where both Promoter and Institutional changes are flat at 0%.

Despite a minimal increase in Promoter holdings, the overall lack of momentum from both Institutions and the Public signals cautious sentiment, aligning with the sector's stagnant performance.